Nutritional Interventions for the Prevention of Cognitive Decline in Patients With Mild Cognitive Impairment and

Qian He1, Kevin Chun Hei Wu1, Adam N Bennett1

  • 1Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.

JMIR Research Protocols
|February 28, 2024
PubMed
Abstract

Insights

Nutritional interventions show promise in delaying cognitive decline in mild cognitive impairment (MCI) and Alzheimer disease (AD). This systematic review synthesizes evidence from 51 studies to guide prevention strategies.

Area of Science:

  • Geriatric Medicine
  • Neuroscience
  • Nutritional Science

Background:

  • Mild cognitive impairment (MCI) represents a transitional stage between normal aging and severe neurodegenerative disorders like Alzheimer disease (AD).
  • Individuals with MCI face an elevated risk of progressing to AD.
  • Nutritional interventions offer a potential avenue for delaying or preventing the onset of MCI and AD.

Purpose of the Study:

  • To systematically evaluate the efficacy of diverse nutritional interventions in preventing cognitive decline in patients with MCI or AD.
  • To employ network meta-analysis, pairwise meta-analysis, and systematic review of randomized controlled trials (RCTs) for a comprehensive assessment.

Main Methods:

  • Adherence to the Population, Intervention, Comparison, Outcome (PICO) model and PRISMA-P guidelines.
  • Systematic literature search of PubMed for RCTs, with independent data extraction and risk of bias assessment.
  • Evaluation of evidence quality using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework and meta-analyses to determine intervention effectiveness.

Main Results:

  • Inclusion of 51 studies (27 for AD, 24 for MCI) published between 1999 and 2023, involving 8420 participants.
  • Data extraction completed for all studies by December 2023.
  • Ongoing data analysis with manuscript preparation, targeting publication by the end of 2024.

Conclusions:

  • The study holds significant clinical relevance due to the increasing prevalence of AD and the potential impact of nutrition on cognitive function.
  • Findings will inform evidence-based strategies for MCI and AD prevention and management.
  • Expected to establish reliable recommendations for clinical practice in geriatric care and neurodegenerative disease management.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
105
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
113